**Name of Journal:** *World Journal of Hepatology*

**Manuscript NO:** 57335

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Cohort Study***

**Cannabis use history is associated with increased prevalence of ascites among patients with nonalcoholic fatty liver disease: A nationwide analysis**

Choi CJ *et al*. Cannabis and nonalcoholic fatty liver disease

Catherine J Choi, Stanley H Weiss, Umair M Nasir, Nikolaos T Pyrsopoulos

**Catherine J Choi, Umair M Nasir,** Department of Medicine, Rutgers New Jersey Medical School, Newark, NJ 07101, United States

**Stanley H Weiss,** Department of Medicine, Biostatistics and Epidemiology, Rutgers New Jersey Medical School, Newark, NJ 07103, United States

**Nikolaos T Pyrsopoulos,** Division of Gastroenterology and Hepatology, Department of Medicine, Rutgers-New Jersey Medical School, Newark, NJ 07103, United States

**Author contributions:** Choi CJ designed the study, acquired data, performed statistical analysis, drafted, and edited this manuscript; Weiss SH supervised the design and reviewed statistical analysis of the study and edited the manuscript; Nasir UM acquired data, and edited the draft; Pyrsopoulos NT designed and supervised the study, and edited the manuscript.

**Corresponding author: Nikolaos T Pyrsopoulos, FACP, MD, PhD, Director, Doctor, Professor,** Division of Gastroenterology and Hepatology, Department of Medicine, Rutgers-New Jersey Medical School, 185 S. Orange Avenue, MSB H-535, Newark, NJ 07103, United States. pyrsopni@njms.rutgers.edu

**Received:** June 4, 2020

**Revised:** August 27, 2020

**Accepted:** October 23, 2020

**Published online:**

**Abstract**

BACKGROUND

Recent studies have revealed the endocannabinoid system as a potential therapeutic target in the management of nonalcoholic fatty liver disease (NAFLD). Cannabis use is associated with reduced risk for NAFLD, we hypothesized that cannabis use would be associated with less liver-related clinical complications in patients with NAFLD.

AIM

To assess the effects of cannabis use on liver-related clinical outcomes in hospitalized patients with NAFLD.

METHODS

We performed a retrospective matched cohort study based on querying the 2014 National Inpatient Sample (NIS) for hospitalizations of adults with a diagnosis of NAFLD. The NIS database is publicly available and the largest all-payer inpatient database in the United States. The patients with cannabis use were selected as cases and those without cannabis were selected as controls. Case-control matching at a ratio of one case to two controls was performed based on sex, age, race, and comorbidities. The liver-related outcomes such as portal hypertension, ascites, varices and variceal bleeding, and cirrhosis were compared between the groups.

RESULTS

A total of 49911 weighed hospitalizations with a diagnosis of NAFLD were identified. Of these, 3820 cases were selected as the cannabis group, and 7625 non-cannabis cases were matched as controls. Patients with cannabis use had a higher prevalence of ascites (4.5% *vs* 3.6%), with and without cannabis use, *P* = 0.03. The prevalence of portal hypertension (2.1% *vs* 2.2%), varices and variceal bleeding (1.3% *vs* 1.7%), and cirrhosis (3.7% *vs* 3.6%) was not different between the groups, with and without cannabis use, all *P* > 0.05. Hyperlipidemia, race/ethnicity other than White, Black, Asian, Pacific Islander or Native American, and higher comorbidity score were independent risk factors for ascites in the cannabis group. Among non-cannabis users, obesity and hyperlipidemia were independent protective factors against ascites while older age, Native American and higher comorbidity index were independent risk factors for ascites.

CONCLUSION

Cannabis was associated with higher rates of ascites, but there was no statistical difference in the prevalence of portal hypertension, varices and variceal bleeding, and cirrhosis.

**Key Words:** Nonalcoholic fatty liver disease; Fatty liver; Cannabis; Marijuana use; Liver diseases; Hospitalization

Choi CJ, Weiss SH, Nasir UM, Pyrsopoulos NT. Cannabis use history is associated with increased prevalence of ascites among patients with nonalcoholic fatty liver disease: A nationwide analysis. *World J Hepatol* 2020; In press

**Core Tip:** Recent studies showed the lower prevalence of nonalcoholic fatty liver disease (NAFLD) among cannabis users compared to non-cannabis users, therefore suggestive of cannabis’s modulatory role in the development of NAFLD. However, our case-control matching analysis, based on sex, age, race, and comorbidity, showed cannabis use as independently associated with higher rates of ascites in patients with NAFLD. A conceivable explanation for the finding is the dominant effect of cannabinoid receptor type 1 through its hepatic profibrotic effects in patients with NAFLD.

**INTRODUCTION**

Nonalcoholic fatty liver disease (NAFLD) is now one of the most common liver diseases worldwide, and its global burden is growing[1]. Weight loss remains the primary treatment for NAFLD, and other treatment modalities have been actively studied, including the use of cannabinoids. Emerging evidence suggests that cannabis may play an important role in the management of various chronic liver diseases[2]. A retrospective population study by Adejumo *et al*[3] has shown a dose-dependent reduction in the prevalence of NAFLD with cannabis use, and cannabis has been suggested to suppress or even reverse the development of NAFLD.

The prevalence of NAFLD parallels that of the obesity pandemic, and NAFLD is considered a metabolic disorder where its pathogenesis involves the complex interplay among hormonal, nutritional, and genetic factors[4]. Aside from a significant weight loss, another cornerstone of the management is to reduce cardiovascular, oncologic, and hepatic risk factors for mortality[4,5]. Perhaps, cannabis use can modulate effects on the development and progression of NAFLD through its metabolic risks and its impact on hepatic steatosis.

Cannabis use is associated with increased appetite and calorie consumption, but paradoxically it is associated with reduced risk of obesity and diabetes[6]. In a cross-sectional data by Kim *et al*[6], active cannabis use provided a protective effect against NAFLD, independent of metabolic risks. Yet, there has been conflicting evidence whether or not cannabis induces the progression of chronic liver diseases., but a systemic review by Farooqui *et al*[7] showed that when confirmed by liver biopsy, there was no association between cannabis use and prevalence of hepatic fibrosis. This lack of association is contrary to initial cross-sectional studies by Hézode *et al*[8] and Ishida *et al*[9] who suggested increased fibrosis in patients who use marijuana.

Here, we aimed to measure clinical outcomes of cannabis use at the national level among hospitalized patients with NAFLD. Given the previously demonstrated correlation between cannabis use and reduced prevalence of NAFLD, we hypothesized that cannabis would be associated with fewer liver-related complications in patients than in individuals who did not use cannabis. This is the first database study to investigate cannabinoids’ effects on liver-related outcomes in hospitalized patients with NAFLD. With our study, we hope to alert clinicians of the possible relevance of ascertainment of cannabis use, which in turn might alter future routine assessments to further probe about cannabis use, especially in light of trends showing recent increases in use in the United States.

**MATERIALS AND METHODS**

***Data source and study population***

This study is a retrospective analysis of the 2014 Healthcare Cost and Utilization Project-National Inpatient Sample (HCUP-NIS). The HCUP-NIS is the largest all-payer inpatient database in the United States, comprising more than 40 states with more than 7 million annual hospital discharges[3]. Results were extracted from the NIS database by identifying hospitalized patients older than 18 years with a diagnosis of NAFLD, by using the corresponding International Classification of Diseases codes: 571.8 (other chronic nonalcoholic liver disease). We excluded common secondary causes of intrahepatic fat accumulation by excluding alcoholic liver disease, hemochromatosis, viral hepatitis B and C, primary biliary cirrhosis, autoimmune hepatitis, and toxic liver disease. The HCUP-NIS is publicly accessible, de-identified database, and it is considered a limited database. Under Health Insurance Portability and Accountability Act, a limited database does not require a review by the institutional review board (IRB). Therefore, Rutgers IRB approval was deemed not required in our study.

***Model design***

Patients with NAFLD with cannabis use were selected as cases, and those without cannabis use were used to produce the control group through case-control matching at a ratio of one case to two controls, on the basis of sex, age, race, and comorbidities. Sex was binary (women or men), race was categorical (White, Black, Hispanic, Asian or Pacific Islander, Native American, and other), and obesity was binary (no obesity or obesity). The age was converted into eight categorical variables for different age groups: 18-27, 28-37, 38-47, 48-57, 58-67, 68-77, 78-87, and 88 or older. The elixhauser comorbidity index (ECI) was used to assess comorbidities in patients. ECI is a method of categorizing comorbidities on the basis of the International Classification of Diseases, which calculates a weighted sum of each of the presence of 29 binary comorbidities[10]. ECI uses 29 of the Agency for Healthcare Research and Quality comorbidity indicators to predict hospital use and in-hospital mortality[11,12]. In our study, the ECI score ranged from -21 to 44, with a mean score of 3. ECI was converted into four groups: ECI ≤ 0, 1-5, 6-10, and ≥ 11.

***Outcomes and predictive variables***

The primary outcomes of the study were inpatient mortality, advanced liver disease-related complications including portal hypertension, ascites, varices and variceal bleeding, cirrhosis, and spontaneous bacterial peritonitis (SBP), as presented in Table 1. SBP and inpatient mortality were not included in our final analysis as it was not possible to conduct meaningful analysis due to their small sample sizes. For each hospitalization, baseline demographics and hospital characteristics were obtained. To address potential confounding factors, we added diabetes, hyperlipidemia, and obesity in Table 1 to compare their baseline prevalence between the case control groups.

***Statistical analyses***

A biomedical statistical expert (SHW) reviewed statistical analysis. All data analyses were conducted using SPSS, version 26 (IBM Corp, Armonk, NY, United States). NIS is based on a complex sampling design that includes stratification, clustering, and weighting. Weighting of patient-level observations was implemented to obtain estimates for the entire population in the United States of hospitalized patients with NAFLD. All statistical analyses were two-tailed, with *P* < 0.05 considered statistically significant. Chi-squared tests were performed to compare categorical data, and Student *t*-tests were performed for continuous data. Univariate linear (continuous outcomes) or logistic (dichotomous outcomes) regression analysis were used to calculate unadjusted odds ratios for the primary outcomes. Subsequently, multivariate regression analysis was used to adjust the results for potential confounders. The final multivariate logistic regression model was built by including those factors associated with the outcome in univariate analysis with *P* < 0.20.

**RESULTS**

***Patient characteristics and demographics***

A total of 3820 patients with NAFLD who had a history of cannabis use were identified in our study. 7625 patients with NAFLD and without cannabis use were matched and placed in the control group. Table 1 summarizes the patients’ baseline characteristics. There was no statistical difference of age, sex, race, ethnicity, and ECI between the groups (*P* > 0.05); therefore, these variables were successfully matched. Yet, patients who used cannabis were slightly younger (mean age: 41.4 *vs* 42.0, *P* = 0.03), and had fewer comorbidities (ECI mean: 2.1 *vs* 3.6, *P* < 0.01), with and without cannabis use. However, the differences in the mean age and mean ECI were not clinically different between the groups.

There were statistical differences in types of insurance in the case group compared with the control group. The proportion of Medicare holders was lower in the cannabis group (16.6% *vs* 17.2%), and a proportion of patients with private insurance was also less in cannabis group (21.9% *vs* 42.6%), with and without cannabis use; all *P* < 0.05. Detailed patient demographics and hospital characteristics are presented in Table 1.

There were fewer patients with metabolic derangement such as diabetes (29.2% *vs* 34.8%), obesity (29.5% *vs* 49.4%), and hyperlipidemia (24.2% *vs* 32.4%) in the cannabis group compared to the non-cannabis group. Of note, 94.1% of the cannabis users were coded under non-dependent use, and due to such a high proportion of non-dependent cannabis use, dose-dependent effects of cannabis on different liver-related complications were not able to be explored.

***Liver disease-related complications***

The cannabis group had a higher prevalence of ascites [4.5% *vs* 3.6%, OR 1.25; 95% confidence interval (CI): 1.02-1.51]. There was no statistical difference in the prevalence of portal hypertension [2.1% *vs* 2.2%, not statistically significant (NS)], varices and variceal bleeding (1.3% *vs* 1.7%, *P* = 0.11), and cirrhosis (3.7% *vs* 3.6%, NS), with and without cannabis use. There was a small sample size, less than 10 in one of the groups for spontaneous bacterial peritonitis and inpatient mortality, and therefore not included in the analysis. Detailed chronic liver disease-related complications are presented in Table 1.

***Healthcare resource utilization associated with index admission***

The mean length of stay was longer for those who used cannabis compared to those who did not use cannabis (5.1 d *vs* 4.9 d), but this difference was not statistically different, *P* = 0.18. Total hospitalization charges were lower for patients who used cannabis ($42503) compared with those who did not use cannabis ($43183), but this difference was also not statistically different either.

***Independent predictors of ascites***

The variables found to be independent predictors of ascites among cannabis users were hyperlipidemia (aOR 1.53; 95%CI: 1.08-2.17), racial group other than White, Black, Hispanic, Asian, Pacific Islanders or Native American (aOR 2.57; 95%CI: 1.24-5.31), and higher comorbidity index (aOR 1.08; 95%CI: 1.07-1.10), all *P* < 0.05. Among patients who did not use cannabis, older age (aOR 1.02; 95%CI: 1.01-1.03), Native Americans (aOR 2.60; 95%CI: 1.03-6.61), and higher comorbidity index (aOR 1.05; 95%CI: 1.04-1.06) were independent predictor of ascites. However, in the same group, obesity (aOR 0.61; 95%CI: 0.46-0.81) and hyperlipidemia (aOR 0.59; 95%CI: 0.44-0.80) were independent protective factors against ascites, all *P* < 0.05. The univariate and multivariate logistic regression analysis for ascites is further delineated in Table 2.

**DISCUSSION**

Cannabis is produced from *Cannabis sativa*, known as the marijuana plant, whichcontains more than 60 active chemical compounds called cannabinoids[3,13]. The primary effects of cannabinoids come from activation of cannabinoid receptors: the two types of G-protein coupled cannabinoid receptors, cannabinoid receptor type 1 (CB1) and cannabinoid receptor type 2 (CB2)[7,14]. CB1 is primarily expressed in the brain while CB2 in immune tissue, and under normal physiologic conditions both CB1 and CB2 are very weakly expressed by the liver[15]. However, an upregulation of these receptors are markedly induced in the human liver with cirrhosis[16,17]. The levels of CB1 are six times greater in patients with chronic hepatitis C compared to control while twice greater in patients with cirrhosis compared to those at a lower fibrosis state[18-20]. CB1 and CB2 exert opposite effects on the liver; CB1 has profibrogenic properties while activation of CB2 in mice has been associated with antifibrotic and anti-inflammatory properties[7].

The most active and best-studied cannabinoids are tetrahydrocannabinol (THC) and cannabidiol (CBD)[7,13]. Both THC and CBD act on CB-1 and CB2, but they have different affinities for the receptors. CB1 activation has been shown to have pro-inflammatory effects and to be involved in hepatic fibrosis and steatosis[3,21]. For instance, in CB1 null mice, CB1 blockers increase fatty acid oxidation and decrease hepatic inflammation and lipogenesis[22]. In contrast, CB2 exerts anti-inflammatory effects. CB2 activation has also been shown to suppress obesity and steatohepatitis and to protect the liver from ischemia-reperfusion injury[3]. THC preferentially activates the CB1 pathway, whereas CBD triggers the dominant activation of CB2[3]. The clinical impact of receptor expression and the ratio of activated CB1 and CB2 are unclear among patients with NAFLD. Given the previous evidence of opposite hepatic effects of CB1 and CB2, it is conceivable to suspect the overall cannabinoid effects from both receptors. Ascites is the only liver-related complication that was significantly different between cannabis and non-cannabis groups out of the complications tested in our study, (OR 1.25; 95%CI: 1.02-1.51). Therefore, a possible explanation for higher prevalence of ascites is the dominant hepatic effects of activated CB1 compared to CB2.

Because marijuana use remains illegal in many states in the United States, most marijuana consumed is often not produced under a controlled setting. Therefore, marijuana varies in its contents and has a risk of containing other chemical contaminants, and it also varies in the amounts of active cannabinoids[23]. Different modes of administration along with dynamic pharmacokinetic processes of cannabinoids lead to different bioavailabilities of active cannabinoids ingested. The most common administration route is smoking through cigarettes, pipes, or water pipes[24]. Smoking is the principal route of cannabis administration as it provides a rapid and efficient delivery to the brain, and the ability to titrate dose to the desired effect[25]. The different inhalation methods lead to inconsistent delivery of cannabinoids in the body, thus making control of the dose of active cannabinoids difficult[23]. Oral administration of cannabis involves a slower absorption, and therefore it has a slower, more-delayed peak of THC, one of the primary psychoactive components of cannabis[25]. Wall *et al*[26] reported oral THC bioavailability as 10%-20%. Therefore, many cannabis users prefer smoking due to a quick onset of effects, but smoking is generally not recommended for therapeutic use[25]. Unfortunately, the mode of cannabis use is not systematically recorded in the NIS, and our retrospective study would be unlikely to reliably capture mode data to compare different modes in the cannabis group. A large prospective study in which mode and dose of cannabis would be ascertained and monitored would be of interest to study the effects of dose and mode on the clinical outcomes.

The patients who used cannabis had higher prevalence of ascites compared to non-cannabis group (OR 1.25; 95%CI: 1.02-1.51). Possible explanations for this finding can be related to 1) hypoalbuminemia due to the toxicity of cannabis use or 2) lower body mass, which is a potential indicator for inadequate nutritional status. Hypoalbuminemia was described as a spectrum of toxic reactions from intravenous cannabis use along with fulminant gastroenteritis, toxic hepatitis, acute renal failure, electrolyte disturbances, leukocytosis, anemia, and relative thrombocytopenia from a study of 4 cases of intravenous cannabis use by Payne *et al*[27] in 1975. Serum albumin is the most abundant plasma protein and therefore binding to albumin is a key determinant of the drug efficacy, distribution and possible toxicity of cannabinoids[28]. The increase in plasma albumin may reduce the unbound fraction of cannabinoids, which further reduces the efficacy of the drug[28].Along the same reasoning, it is conceivable to hypothesize more cannabinoid toxicity in patients with hypoalbuminemia due to more unbound cannabinoids. A study by Blüml *et al*[29] showed an inverse relationship between body mass index (BMI) and illicit drug use including cannabis use among young males, and therefore along with the toxicity of high-dose cannabis use, hypoalbuminemia from poor nutritional status may explain higher rate of ascites in cannabis users due to the low oncotic pressure from hypoalbuminemia. The forementioned explanation for hypoalbuminemia can partly explain the isolated finding of higher rates of ascites in cannabis users without higher rates of portal hypertension, varices and variceal bleeding and cirrhosis. Another explanation of such finding can be related to a lack of long-term follow-up. As the NIS is limited to hospitalized data, a spectrum of clinical presentations of decompensated cirrhosis such as varices and variceal bleeding and actual clinical diagnosis of cirrhosis outside of hospital may not be captured in our study design. Further studies with a long-term follow-up investigating cannabis use in patients with NAFLD are warranted to further evaluate the rates of clinical manifestations of decompensated cirrhosis.

The patients with cannabis group had a higher rate of ascites compared to the non-cannabis group despite higher baseline rates of metabolic risks in non-cannabis group such as diabetes, hyperlipidemia, and obesity. This suggests that cannabis may not be a magic bullet for the management of NAFLD. In cannabis group, higher comorbidity index was an independent risk factor for ascites, and this is expected as older patients with more comorbidity are associated with worse prognosis in patients with chronic liver diseases. In non-cannabis group, age and higher comorbidity were again independent risk factors for ascites. However, strikingly obesity (aOR 0.61; 95%CI: 0.46-0.81) and hyperlipidemia (aOR 0.59; 95%CI: 0.44-0.88) were independent protective factors against ascites in patients with NAFLD who did not use cannabis. A possible explanation for this finding can be related to nutritional status in patients with ascites. Metabolic derangements such as obesity and insulin resistance predispose to NAFLD[30], and therefore they are risk factors for development of NAFLD. However, at terminal stage of liver disease with evidence of decompensation such as ascites, the increased BMI and appropriate albumin levels can be protective against developing ascites. Previous studies showed that muscle wasting was worse in obese patients[31] with cirrhosis, and these patients are at high risk for fat-and water-soluble vitamin depletion[32]. Therefore, our finding of the association between obesity and reduced prevalence of ascites is surprising. However, a study by Li *et al*[33] showed that patients with higher BMI had lower rates of liver-related mortality compared to lower BMI among patients with cirrhosis and hepatocellular carcinoma. We were not able to measure nutritional status in our study; therefore although obesity often co-exists with malnutrition, we can speculate that our study population with an obesity diagnosis may have better nutrition than those without obesity.

Patients with cirrhosis are at higher risk for poor tolerance of fasting, and therefore aggressive energy restriction is avoided in these patients[34]. Due to the risk of sarcopenia with weight loss, patients who are advised to lose weight should be monitored for changes in body muscle mass and muscle strength[34]. Therefore, increased BMI in the setting of end-stage liver disease may suggest better nutritional status compared to non-obese patients. In the meantime, sarcopenic obesity is associated with a higher rate of mortality in patients with cirrhosis, and therefore further distinction between sarco obesity and obesity is warranted. The impairment of liver lipogenesis is prominent in decompensated NAFLD, and subsequently low levels of cholesterol in advanced NAFLD is not surprising. Therefore, in patients with decompensated NAFLD as seen with ascites, hyperlipidemia and obesity can be associated with less prevalence of ascites due to a better nutritional status in this vulnerable population with advanced liver disease.

Among cannabis users, hyperlipidemia was an independent risk factor for ascites (aOR 1.53; 95%CI: 1.08-2.17). Previous few studies showed significantly diminished level of serum high-density lipoprotein, low-density lipoprotein, and total cholesterol in liver cirrhosis[35,36]. Similarly, some studies showed a decrease in triglyceride in cirrhosis[36]. Liver biosynthesis is reduced with the progression of cirrhosis[37]. Although there were mixed findings of the relationship between cholesterol values and cirrhosis, our findings are compatible with the abovementioned relationship.

This is the national retrospective study to evaluate the clinical effects of cannabis among hospitalized patients with NAFLD at the national level. Strengths of our manuscript are a large sample size as well as the use of case-control matching analysis, where the groups are matched on age, sex, race, comorbidity. To address potential confounding factors, we also examined diabetes, hyperlipidemia, obesity as co-variates in multi-variate analysis.

Despite these strengths, our study has some limitations that are mainly associated with the nature of large population database studies, in which patients are typically not routinely tested for cannabis use upon admission, and the diagnosis of cannabis use is often made from patient reports. Therefore, unless patients are forthcoming with their caregivers regarding cannabis use, cannabis use may be missed or under-coded. The NIS also relies on accurate billing by clinicians to accurately record diseases and complications, which may lead to an underestimate of diagnosis. In addition, monitoring long-term clinical outcomes, such as liver-related complications not recorded in NIS, remains challenging.

Another limitation of this study is the inability to characterize different concentrations or modes of cannabis administration. 94.1% of the cannabis users were coded under non-dependent use, and due to the limited sample size, we could not provide dose-dependent data. A possible explanation for the low baseline percentage of dependent cannabis use is a lack of available data, limited current routine clinician assessment, or truly low number of patients who abuse cannabis. We were unable to characterize the concentrations and effects of each cannabinoid, as well as the dose-dependent effects of these cannabinoids. Long-term randomized controlled studies with different levels of cannabinoid types and amounts are warranted to better understand each cannabinoid’s effects on the cannabinoid system in the body.

**CONCLUSION**

In conclusion, this was the first database study investigating progressive liver disease-related clinical outcomes in hospitalized patients with NAFLD. Cannabis was associated with higher rates of ascites, but there was no statistical difference in the prevalence of portal hypertension, varices and variceal bleeding, and cirrhosis. In the cannabis group, hyperlipidemia was an independent risk factor for ascites but in non-cannabis group hyperlipidemia and obesity were independent protective factors against ascites. A large prospective study in which mode and dose of cannabis would be ascertained and monitored would be of interest.

**ARTICLE HIGHLIGHTS**

***Research background***

The impact of cannabis on the progression of chronic liver diseases has been unclear in prior studies. Systemic reviews showed no association between the increased prevalence of hepatic fibrosis and cannabis use, but cannabis use was still associated with a reduced prevalence of nonalcoholic fatty liver disease.

***Research motivation***

Because of the modulatory effects of cannabis on risk factors for the development of nonalcoholic fatty liver disease (NAFLD), we wanted to measure the correlation between cannabis use and clinical outcomes related to chronic liver diseases. Without clear evidence between the cannabis use and progression of established NAFLD, it is critical for clinicians to educate the patients on the use of cannabis due to limited evidence on cannabinoid effects. Therefore, our study is motivated to alert clinicians of the possible relevance of ascertainment of cannabis use, which in turn might alter future routine assessments to further probe about cannabis use, especially in light of trends showing recent increases in use in the United States.

***Research objectives***

Our study aimed to assess the association between cannabis use and clinical liver-related outcomes among hospitalized patients with NAFLD.

***Research methods***

In our study, we performed a retrospective matched cohort study for hospitalized adult patients with NAFLD. Case-control matching at a ratio of one case to two controls was performed based on sex, age, race, and comorbidities to adjust for confounders. The liver-related complications including portal hypertension, ascites, varices and variceal bleeding, and cirrhosis were measured and compared between two groups.

***Research results***

The cannabis group had a higher prevalence of ascites compared to patients with NAFLD who did not use cannabis. Obesity and hyperlipidemia were independent protective effects against ascites in the non-cannabis group.

***Research conclusions***

Cannabis use was associated with higher rates of ascites despite higher rates of metabolic risks in the non-cannabis group such as diabetes, hyperlipidemia, and obesity. This suggests that cannabis may not be a magic bullet for the management of NAFLD, and therefore judicious use of cannabis in advanced NAFLD is warranted.

***Research perspectives***

A large prospective study in which mode and dose of cannabis use would be warranted to further explore the effects of administration mode and dose of cannabis on the liver-related clinical complications.

**REFERENCES**

1 **Alswat KA**, Fallatah HI, Al-Judaibi B, Elsiesy HA, Al-Hamoudi WK, Qutub AN, Alturaify N, Al-Osaimi A. Position statement on the diagnosis and management of non-alcoholic fatty liver disease. *Saudi Med J* 2019; **40**: 531-540 [PMID: 31219486 DOI: 10.15537/smj.2019.6.23980]

2 **Patsenker E**, Stickel F. Cannabinoids in liver diseases. *Clin Liver Dis (Hoboken)* 2016; **7**: 21-25 [PMID: 31041021 DOI: 10.1002/cld.527]

3 **Adejumo AC**, Alliu S, Ajayi TO, Adejumo KL, Adegbala OM, Onyeakusi NE, Akinjero AM, Durojaiye M, Bukong TN. Cannabis use is associated with reduced prevalence of non-alcoholic fatty liver disease: A cross-sectional study. *PLoS One* 2017; **12**: e0176416 [PMID: 28441459 DOI: 10.1371/journal.pone.0176416]

4 **Carr RM**, Oranu A, Khungar V. Nonalcoholic Fatty Liver Disease: Pathophysiology and Management. *Gastroenterol Clin North Am* 2016; **45**: 639-652 [PMID: 27837778 DOI: 10.1016/j.gtc.2016.07.003]

5 **Fu Z**, Gilbert ER, Liu D. Regulation of insulin synthesis and secretion and pancreatic Beta-cell dysfunction in diabetes. *Curr Diabetes Rev* 2013; **9**: 25-53 [PMID: 22974359]

6 **Kim D**, Kim W, Kwak MS, Chung GE, Yim JY, Ahmed A. Inverse association of marijuana use with nonalcoholic fatty liver disease among adults in the United States. *PLoS One* 2017; **12**: e0186702 [PMID: 29049354 DOI: 10.1371/journal.pone.0186702]

7 **Farooqui MT**, Khan MA, Cholankeril G, Khan Z, Mohammed Abdul MK, Li AA, Shah N, Wu L, Haq K, Solanki S, Kim D, Ahmed A. Marijuana is not associated with progression of hepatic fibrosis in liver disease: a systematic review and meta-analysis. *Eur J Gastroenterol Hepatol* 2019; **31**: 149-156 [PMID: 30234644 DOI: 10.1097/MEG.0000000000001263]

8 **Hézode C**, Roudot-Thoraval F, Nguyen S, Grenard P, Julien B, Zafrani ES, Pawlotsky JM, Dhumeaux D, Lotersztajn S, Mallat A. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. *Hepatology* 2005; **42**: 63-71 [PMID: 15892090 DOI: 10.1002/hep.20733]

9 **Ishida JH**, Peters MG, Jin C, Louie K, Tan V, Bacchetti P, Terrault NA. Influence of cannabis use on severity of hepatitis C disease. *Clin Gastroenterol Hepatol* 2008; **6**: 69-75 [PMID: 18166478 DOI: 10.1016/j.cgh.2007.10.021]

10 **Healthcare Cost and Utilization Project (HCUP).** HCUP Elixhauser Comorbidity Software, Verson 3.7 [Internet]. Agency Healthc. Res. Qual. 2017; Rockville, MD. 2017. Available from: http://www.hcup-us.ahrq.gov/toolssoftware/comorbidity/comorbidity.jsp

11 **Elixhauser A**, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. *Med Care* 1998; **36**: 8-27 [PMID: 9431328 DOI: 10.1097/00005650-199801000-00004]

12 **Rotundo L**, Afridi F, Feurdean M, Ahlawat S. Effect of hospital teaching status on endoscopic retrograde cholangiopancreatography mortality and complications in the USA. *Surg Endosc* 2020; : [PMID: 32030551 DOI: 10.1007/s00464-020-07403-z]

13 **Quezada SM**, Cross RK. Cannabis and Turmeric as Complementary Treatments for IBD and Other Digestive Diseases. *Curr Gastroenterol Rep* 2019; **21**: 2 [PMID: 30635796 DOI: 10.1007/s11894-019-0670-0]

14 **Esfandyari T**, Camilleri M, Ferber I, Burton D, Baxter K, Zinsmeister AR. Effect of a cannabinoid agonist on gastrointestinal transit and postprandial satiation in healthy human subjects: a randomized, placebo-controlled study. *Neurogastroenterol Motil* 2006; **18**: 831-838 [PMID: 16918762 DOI: 10.1111/j.1365-2982.2006.00834.x]

15 **Baldassarre M**, Giannone FA, Napoli L, Tovoli A, Ricci CS, Tufoni M, Caraceni P. The endocannabinoid system in advanced liver cirrhosis: pathophysiological implication and future perspectives. *Liver Int* 2013; **33**: 1298-1308 [PMID: 23890208 DOI: 10.1111/liv.12263]

16 **Julien B**, Grenard P, Teixeira-Clerc F, Van Nhieu JT, Li L, Karsak M, Zimmer A, Mallat A, Lotersztajn S. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. *Gastroenterology* 2005; **128**: 742-755 [PMID: 15765409 DOI: 10.1053/j.gastro.2004.12.050]

17 **Lotersztajn S**, Julien B, Teixeira-Clerc F, Grenard P, Mallat A. Hepatic fibrosis: molecular mechanisms and drug targets. *Annu Rev Pharmacol Toxicol* 2005; **45**: 605-628 [PMID: 15471534 DOI: 10.1146/annurev.pharmtox.45.120403.095906]

18 **Xu X**, Liu Y, Huang S, Liu G, Xie C, Zhou J, Fan W, Li Q, Wang Q, Zhong D, Miao X. Overexpression of cannabinoid receptors CB1 and CB2 correlates with improved prognosis of patients with hepatocellular carcinoma. *Cancer Genet Cytogenet* 2006; **171**: 31-38 [PMID: 17074588 DOI: 10.1016/j.cancergencyto.2006.06.014]

19 **van der Poorten D**, Shahidi M, Tay E, Sesha J, Tran K, McLeod D, Milliken JS, Ho V, Hebbard LW, Douglas MW, George J. Hepatitis C virus induces the cannabinoid receptor 1. *PLoS One* 2010; **5**: [PMID: 20862263 DOI: 10.1371/journal.pone.0012841]

20 **Toyoda M,** Kitaoka A, Machida K, Nishinakagawa T, Yada R, Kohjima M, Kato M, Kotoh K, Sakamoto N, Shiota G, Nakamuta M, Nakashima M, Enjoji M. Association between lipid accumulation and the cannabinoid system in Huh7 cells expressing HCV genes. *Int J Mol Med* 2011; **27:** 619-624 [PMID: 21331443 DOI: 10.3892/ijmm.2011.622]

21 **Trebicka J**, Racz I, Siegmund SV, Cara E, Granzow M, Schierwagen R, Klein S, Wojtalla A, Hennenberg M, Huss S, Fischer HP, Heller J, Zimmer A, Sauerbruch T. Role of cannabinoid receptors in alcoholic hepatic injury: steatosis and fibrogenesis are increased in CB2 receptor-deficient mice and decreased in CB1 receptor knockouts. *Liver Int* 2011; **31**: 860-870 [PMID: 21645218 DOI: 10.1111/j.1478-3231.2011.02496.x]

22 **Kirkham TC,** Tucci SA. Endocannabinoids in appetite control and the treatment of obesity. *CNS Neurol Disord Drug Targets* 2006; 5: 272-292 [PMID: 16787229 DOI: 10.2174/187152706777452272]

23 **Urits I**, Borchart M, Hasegawa M, Kochanski J, Orhurhu V, Viswanath O. An Update of Current Cannabis-Based Pharmaceuticals in Pain Medicine. *Pain Ther* 2019; **8**: 41-51 [PMID: 30721403 DOI: 10.1007/s40122-019-0114-4]

24 **Goyal H**, Singla U, Gupta U, May E. Role of cannabis in digestive disorders. *Eur J Gastroenterol Hepatol* 2017; **29**: 135-143 [PMID: 27792038 DOI: 10.1097/MEG.0000000000000779]

25 **Huestis MA**. Human cannabinoid pharmacokinetics. *Chem Biodivers* 2007; **4**: 1770-1804 [PMID: 17712819 DOI: 10.1002/cbdv.200790152]

26 **Wall ME**, Sadler BM, Brine D, Taylor H, Perez-Reyes M. Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women. *Clin Pharmacol Ther* 1983; **34**: 352-363 [PMID: 6309462 DOI: 10.1038/clpt.1983.179]

27 **Payne RJ,** Brand SN. The toxicity of intravenously used marihuana. *JAMA* 1975; **233:** 351-354 [PMID: 1173650]

28 **Leboffe L,** di Masi A, Trezza V, Polticelli F, Ascenzi P. Human serum albumin: A modulator of cannabinoid drugs. *IUBMB Life* 2017; **69:** 834-840 [PMID: 28976704 DOI: 10.1002/iub.1682]

29 **Blüml V**, Kapusta N, Vyssoki B, Kogoj D, Walter H, Lesch OM. Relationship between substance use and body mass index in young males. *Am J Addict* 2012; **21:** 72-77 [PMID: 22211349 DOI: 10.1111/j.1521-0391.2011.00192.x]

30 **Katsiki N**, Mikhailidis DP, Mantzoros CS. Non-alcoholic fatty liver disease and dyslipidemia: An update. *Metabolism* 2016; **65**: 1109-1123 [PMID: 27237577 DOI: 10.1016/j.metabol.2016.05.003]

31 **Vidot H**, Kline K, Cheng R, Finegan L, Lin A, Kempler E, Strasser SI, Bowen DG, McCaughan GW, Carey S, Allman-Farinelli M, Shackel NA. The Relationship of Obesity, Nutritional Status and Muscle Wasting in Patients Assessed for Liver Transplantation. *Nutrients* 2019; **11**: [PMID: 31487854 DOI: 10.3390/nu11092097]

32 **Schiavo L**, Busetto L, Cesaretti M, Zelber-Sagi S, Deutsch L, Iannelli A. Nutritional issues in patients with obesity and cirrhosis. *World J Gastroenterol* 2018; **24**: 3330-3346 [PMID: 30122874 DOI: 10.3748/wjg.v24.i30.3330]

33 **Li Q**, Xing H, Liu D, Li H. Negative impact of low body mass index on liver cirrhosis patients with hepatocellular carcinoma. *World J Surg Oncol* 2015; **13**: 294 [PMID: 26444667 DOI: 10.1186/s12957-015-0713-4]

34 **Eslamparast T**, Montano-Loza AJ, Raman M, Tandon P. Sarcopenic obesity in cirrhosis-The confluence of 2 prognostic titans. *Liver Int* 2018; **38**: 1706-1717 [PMID: 29738109 DOI: 10.1111/liv.13876]

35 **Cicognani C**, Malavolti M, Morselli-Labate AM, Zamboni L, Sama C, Barbara L. Serum lipid and lipoprotein patterns in patients with liver cirrhosis and chronic active hepatitis. *Arch Intern Med* 1997; **157**: 792-796 [PMID: 9125012 DOI: 10.1001/archinte.1997.00440280120012]

36 **Ghadir MR**, Riahin AA, Havaspour A, Nooranipour M, Habibinejad AA. The relationship between lipid profile and severity of liver damage in cirrhotic patients. *Hepat Mon* 2010; **10**: 285-288 [PMID: 22312394]

37 **Phukan JP**, Sinha A, Deka JP. Serum lipid profile in alcoholic cirrhosis: A study in a teaching hospital of north-eastern India. *Niger Med J* 2013; **54**: 5-9 [PMID: 23661892 DOI: 10.4103/0300-1652.108886]

**Footnotes**

**Institutional review board statement:** The activities described in our study do not meet the regulatory definition of human subjects research, and therefore our study was deemed not requiring approval by Rutgers Institutional Review Board (IRB).

**Conflict-of-interest statement:** Dr. Pyrsopoulos is a recipient of research grants from Mallinckrodt, Valeant, Gilead, Bayer, Beigene, Genfit, Prometheus, Grifols, Intercept, Zydus, and Eisai. Dr. Pyrsopoulos also has served as a consultant for Bayer, and Eisai. The other authors have no potential conflicts of interest to report.

**STROBE statement:** The authors have read the STROBE Statement—a checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—a checklist of items.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** June 4, 2020

**First decision:** July 30, 2020

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): 0

Grade D (Fair): D, D, D

Grade E (Poor): 0

**P-Reviewer:** Chao HW, Moretti R **S-Editor:** Fan JR **L-Editor: P-Editor:**

**Table 1 Patient demographics, hospital characteristics, and outcomes among patients with nonalcoholic fatty liver disease, by history of cannabis use**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Cannabis users, *n* = 3820** | **Non-cannabis users, *n* = 7625** | ***P* value** | |
| Sex |  |  | NS1 | | |
| Female | 36.0% | 36.1% |  | | |
| Male | 64.0% | 63.9% |  | | |
| Patient age, mean (SD) | 41.4 (12.9) | 42.0 (12.9) | 0.032 | | |
| Patient age, in 10 years age groups3 |  |  | NS4 | | |
| 18-27 | 16.8% | 16.6% |  | | |
| 28-37 | 25.3% | 25.3% |  | | |
| 38-47 | 20.4% | 20.5% |  | | |
| 48-57 | 25.8% | 25.8% |  | | |
| 58-67 | 11.0% | 11.0% |  | | |
| 68-77 | 0.8% | 0.8% |  | | |
| Race/ethnicity |  |  | NS4 | | |
| White | 60.6% | 60.7% |  | | |
| Black | 21.6% | 21.6% |  | | |
| Hispanic | 13.9% | 13.9% |  | | |
| Asian or pacific islander | 0.4% | 0.4% |  | | |
| Native American | 0.9% | 0.9% |  | | |
| Others | 2.6% | 2.4% |  | | |
| ECI, mean (SD) | 2.1 (9.4) | 3.6 (8.1) | < 0.012 | | |
| ECI, by category |  |  | NS4 |
| ≤ 0 | 47.6% | 47.7% |  | | |
| 1-5 | 15.8% | 15.9% |  | | |
| 6-10 | 19.6% | 19.5% |  | | |
| 11 or higher | 16.9% | 16.9% |  | | |
| Insurance |  |  | < 0.054 | | |
| Medicare | 16.6% | 17.2% |  | | |
| Medicaid | 42.8% | 30.5% |  | | |
| Private | 21.9% | 42.6% |  | | |
| Self-Pay | 13.4% | 6.0% |  | | |
| Others | 5.4%5 | 3.7% |  | | |
| Cannabis abuse |  |  |  | | |
| Non-dependent use | 94.1% | 0 (by definition) |  | | |
| Dependent use | 5.9% | 0 (by definition) |  | | |
| Length of stay (days) | 5.1 | 4.9 | 0.182 | | |
| Total hospitalization charges | $42503 | $43183 | NS2 | | |
| Comorbidities |  |  |  | | |
| Diabetes | 29.2% | 34.8% | < 0.055 | | |
| Obesity | 29.5% | 49.4% | < 0.055 | | |
| Hyperlipidemia | 24.2% | 32.4% | < 0.055 | | |
| Clinical outcomes |  |  |  | | |
| Portal hypertension | 80 (2.1%) | 165 (2.2%) | NS5 | | |
| Ascites | 170 (4.5%) | 275 (3.6%) | 0.035 | | |
| Varices and variceal bleeding | 50 (1.3%) | 130 (1.7%) | 0.115 | | |
| Cirrhosis | 140 (3.7%) | 275 (3.6%) | NS5 | | |

1Chi-square, 2-tailed; 2Student *t*-test, 2-tailed; 3Patient ages ranged from 18 to 73, there was no one over 78; 4Chi-square, 2-tailed, for 2 by *n* table: Statistical significance demonstrates that the two groups differ; 5Condition absent *vs* present in the 2 groups, chi-square, 2-tailed. NS: Not statistically significant; ECI: Elixhauser comorbidity index.

**Table 2 Independent predictors of ascites among patients with nonalcoholic fatty liver disease, stratified by cannabis use history**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Cannabis users (*n* = 3820)** | | | | | **Non-cannabis users (*n* = 7625)** | | | | |
| **Ascites** | **OR (95% CI)** | ***P* value** | **aOR (95% CI)** | ***P* value** | **Ascites** | **OR (95% CI)** | ***P* value** | **aOR (95% CI)** | ***P* value** |
|  | Univariate logistic regression |  | Multivariate logistic regression1 |  |  | Univariate logistic regression |  | Multivariate logistic regression1 |  |
| Diabetes | 1.17 (0.84-1.62) | NS |  |  | Diabetes | 1.16 (0.91-1.49) | 0.23 |  |  |
| Obesity | 1.00 (0.71-1.40) | NS |  |  | Obesity | 0.41 (0.31-0.53) | < 0.01 | 0.61 (0.46-0.81) | < 0.01 |
| Hyperlipidemia | 1.32 (0.94-1.85) | 0.11 | 1.53 (1.08-2.17) | 0.02 | Hyperlipidemia | 0.57 (0.43-0.77) | < 0.01 | 0.59 (0.44-0.80) | < 0.01 |
| Age (continuous) | 0.99 (0.98-1.01) | 0.22 |  |  | Age (continuous) | 1.02 (0.01-1.03) | < 0.01 | 1.02 (1.01-1.03) | < 0.01 |
| Race/ethnicity (categoric) |  |  |  |  | Race/ethnicity (categoric) |  |  |  |  |
| White | Reference |  |  |  | White | Reference |  |  |  |
| Black | 1.13 (0.78-1.64) | NS |  |  | Black | 0.80 (0.58-1.10) | 0.16 |  |  |
| Hispanic | 0.87 (0.53-1.42) | NS |  |  | Hispanic | 1.00 (0.70-1.42) | NS |  |  |
| Asian or pacific islander | 1 |  |  |  | Asian or pacific islander | 1 |  |  |  |
| Native American | 2 |  |  |  | Native American | 1.96 (0.78-4.92) | 0.15 | 2.60 (1.03-6.61) | 0.04 |
| Others | 2.46 (1.24-4.87) | 0.01 | 2.57 (1.24-5.31) | 0.01 | Others | 0.71 (0.29-1.74) | NS |  |  |
| Comorbidity (continuous) | 1.08 (1.07-1.10) | < 0.01 | 1.08 (1.07-1.10) | < 0.01 | Comorbidity (continuous) | 1.06 (1.05-1.07) | < 0.01 | 1.05 (1.04-1.06) | < 0.01 |
| Sex (female) | 0.80 (0.58-1.09) | 0.15 |  |  | Sex (female) | 0.99 (0.77-1.27) | NS |  |  |

1Univariate analysis with screening *P* < 0.02 was used to determine variables to include in the final multivariate analysis. Hyperlipidemia, Race/ethnicity, comorbidity index, and sex included in the regression; 2Univariate analysis with screening *P* < 0.02 was used again, and obesity, hyperlipidemia, age, race/ethnicity, and comorbidity index were included in the multivariate regression. NS: Not statistically significant.